Oncogeni Ltd, a company founded in 2019 by the British scientist and Nobel Laureate Martin Evans is to be acquired by Roquefort Therapeutics Plc in order to progress its preclinical assets for cancer. The all-share transaction, announced on 22 June, has been valued at around £4 million. Concurrently, the enlarged company will have two new investors: Daiichi Sankyo Co Ltd and the venture capital investor CH Health.
